{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:21:57Z","timestamp":1793650917253,"version":"4.5.1"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Supported in part by the Goldenberg-Shanahan Family Fund, the Harold Grinspoon Foundation, the Alomran family and Endowed Chair (JNR), and the Atai Foundation Research Fellowship (AN)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"DOI":"10.1038\/s44161-025-00608-2","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T05:03:45Z","timestamp":1738731825000},"page":"131-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cardiovascular effects and safety of classic psychedelics"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6128-7864","authenticated-orcid":false,"given":"Acile","family":"Nahlawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon M.","family":"Ptaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy N.","family":"Ruskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"608_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1556\/2054.2019.008","volume":"3","author":"G Samorini","year":"2019","unstructured":"Samorini, G. The oldest archeological data evidencing the relationship of Homo sapiens with psychoactive plants: a worldwide overview. J. Psychedelic Stud. 3, 63\u201380 (2019).","journal-title":"J. Psychedelic Stud."},{"key":"608_CR2","unstructured":"Sessa, B. The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society 2nd edn (Muswell Hill Press, 2017)."},{"key":"608_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30, 1165\u20131180 (2016).","journal-title":"J. Psychopharmacol."},{"key":"608_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619\u2013627 (2016).","journal-title":"Lancet Psychiatry"},{"key":"608_CR5","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno, F. A., Wiegand, C. B., Taitano, E. K. & Delgado, P. L. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive\u2013compulsive disorder. J. Clin. Psychiatry 67, 1735\u20131740 (2006).","journal-title":"J. Clin. Psychiatry"},{"key":"608_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28, 983\u2013992 (2014).","journal-title":"J. Psychopharmacol."},{"key":"608_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser, P. et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J. Nerv. Ment. Dis. 202, 513\u2013520 (2014).","journal-title":"J. Nerv. Ment. Dis."},{"key":"608_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"key":"608_CR9","unstructured":"Compass. COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-Resistant Depression (2018)."},{"key":"608_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330, 843\u2013853 (2023).","journal-title":"JAMA"},{"key":"608_CR11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637\u20131648 (2022).","journal-title":"N. Engl. J. Med."},{"key":"608_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78, 481\u2013489 (2021).","journal-title":"JAMA Psychiatry"},{"key":"608_CR13","unstructured":"MindMed. MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder press release (2024)."},{"key":"608_CR14","doi-asserted-by":"publisher","first-page":"685085","DOI":"10.3389\/fneur.2021.685085","volume":"12","author":"SM Khan","year":"2021","unstructured":"Khan, S. M., Carter, G. T., Aggarwal, S. K. & Holland, J. Psychedelics for brain injury: a mini-review. Front. Neurol. 12, 685085 (2021).","journal-title":"Front. Neurol."},{"key":"608_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fnsyn.2020.00034","volume":"12","author":"SA Vann Jones","year":"2020","unstructured":"Vann Jones, S. A. & O\u2019Kelly, A. Psychedelics as a treatment for Alzheimer\u2019s disease dementia. Front. Synaptic Neurosci. 12, 34 (2020).","journal-title":"Front. Synaptic Neurosci."},{"key":"608_CR16","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/head.12148","volume":"53","author":"SJ Tepper","year":"2013","unstructured":"Tepper, S. J. & Stillman, M. J. Cluster headache: potential options for medically refractory patients (when all else fails). Headache 53, 1183\u20131190 (2013).","journal-title":"Headache"},{"key":"608_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.imlet.2020.10.001","volume":"228","author":"C Thompson","year":"2020","unstructured":"Thompson, C. & Szabo, A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol. Lett. 228, 45\u201354 (2020).","journal-title":"Immunol. Lett."},{"key":"608_CR18","doi-asserted-by":"publisher","first-page":"L191","DOI":"10.1152\/ajplung.00138.2013","volume":"308","author":"F Nau Jr.","year":"2015","unstructured":"Nau, F. Jr. et al. Serotonin 5-HT2 receptor activation prevents allergic asthma in a mouse model. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L191\u2013L198 (2015).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"608_CR19","doi-asserted-by":"publisher","first-page":"14427","DOI":"10.1038\/s41598-021-93787-4","volume":"11","author":"O Simonsson","year":"2021","unstructured":"Simonsson, O., Osika, W., Carhart\u2010Harris, R. & Hendricks, P. S. Associations between lifetime classic psychedelic use and cardiometabolic diseases. Sci. Rep. 11, 14427 (2021).","journal-title":"Sci. Rep."},{"key":"608_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fphar.2016.00035","volume":"7","author":"E Frecska","year":"2016","unstructured":"Frecska, E., Bokor, P. & Winkelman, M. The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization. Front. Pharmacol. 7, 35 (2016).","journal-title":"Front. Pharmacol."},{"key":"608_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1124\/jpet.103.049528","volume":"306","author":"JA May","year":"2003","unstructured":"May, J. A., McLaughlin, M. A., Sharif, N. A., Hellberg, M. R. & Dean, T. R. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J. Pharmacol. Exp. Ther. 306, 301\u2013309 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"608_CR22","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","volume":"75","author":"A Ws\u00f3\u0142","year":"2023","unstructured":"Ws\u00f3\u0142, A. Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacol. Rep. 75, 1362\u20131380 (2023).","journal-title":"Pharmacol. Rep."},{"key":"608_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols, D. E. Psychedelics. Pharmacol. Rev. 68, 264\u2013355 (2016).","journal-title":"Pharmacol. Rev."},{"key":"608_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","volume":"66","author":"H Osmond","year":"1957","unstructured":"Osmond, H. A review of the clinical effects of psychotomimetic agents. Ann. N. Y. Acad. Sci. 66, 418\u2013434 (1957).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"608_CR25","doi-asserted-by":"crossref","unstructured":"Jay, M. Mescaline: a Global History of the First Psychedelic (Yale Univ. Press, 2019).","DOI":"10.12987\/9780300245080"},{"key":"608_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/02791072.2019.1581961","volume":"51","author":"JS Aday","year":"2019","unstructured":"Aday, J. S., Bloesch, E. K. & Davoli, C. C. Beyond LSD: a broader psychedelic zeitgeist during the early to mid-20th century. J. Psychoactive Drugs 51, 210\u2013217 (2019).","journal-title":"J. Psychoactive Drugs"},{"key":"608_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0957154X16648822","volume":"27","author":"M Oram","year":"2016","unstructured":"Oram, M. Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration. Hist. Psychiatry 27, 290\u2013306 (2016).","journal-title":"Hist. Psychiatry"},{"key":"608_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/02791072.1991.10472572","volume":"23","author":"RJ Strassman","year":"1991","unstructured":"Strassman, R. J. Human hallucinogenic drug research in the United States: a present-day case history and review of the process. J. Psychoactive Drugs 23, 29\u201338 (1991).","journal-title":"J. Psychoactive Drugs"},{"key":"608_CR29","doi-asserted-by":"publisher","first-page":"174156","DOI":"10.1016\/j.ejphar.2021.174156","volume":"903","author":"DA Fonseca","year":"2021","unstructured":"Fonseca, D. A., Ribeiro, D. M., Tapadas, M. & Cotrim, M. D. Ecstasy (3,4-methylenedioxymethamphetamine): cardiovascular effects and mechanisms. Eur. J. Pharmacol. 903, 174156 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"608_CR30","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.3390\/molecules20022208","volume":"20","author":"X Koenig","year":"2015","unstructured":"Koenig, X. & Hilber, K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 20, 2208\u20132228 (2015).","journal-title":"Molecules"},{"key":"608_CR31","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00213-021-05964-y","volume":"239","author":"G Ona","year":"2021","unstructured":"Ona, G. et al. The adverse events of ibogaine in humans: an updated systematic review of the literature (2015\u20132020). Psychopharmacology 239, 1977\u20131987 (2021).","journal-title":"Psychopharmacology"},{"key":"608_CR32","doi-asserted-by":"crossref","unstructured":"Ray, T. S. Psychedelics and the human receptorome. PLoS ONE 5, e9019 (2010). This article describes the receptor affinity of psychedelic drugs.","DOI":"10.1371\/journal.pone.0009019"},{"key":"608_CR33","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli, A., Moning, O. D., Hoener, M. C. & Liechti, M. E. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur. Neuropsychopharmacol. 26, 1327\u20131337 (2016).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"608_CR34","unstructured":"Joachim, N., Britt, H. & Ulrich, G. In Serotonin (ed. Fatima-Shad, K.) Ch. 13 (IntechOpen, 2017)."},{"key":"608_CR35","doi-asserted-by":"crossref","unstructured":"Neumann, J., Hofmann, B., Dhein, S. & Gergs, U. Cardiac roles of serotonin (5-HT) and 5-HT-receptors in health and disease. Int. J. Mol. Sci. 24, 4765 (2023). A review of the cardiovascular effects of serotonin.","DOI":"10.3390\/ijms24054765"},{"key":"608_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","volume":"111","author":"AJ Kaumann","year":"2006","unstructured":"Kaumann, A. J. & Levy, F. O. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther. 111, 674\u2013706 (2006).","journal-title":"Pharmacol. Ther."},{"key":"608_CR37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s12013-013-9606-8","volume":"67","author":"LM Pavone","year":"2013","unstructured":"Pavone, L. M. & Norris, R. A. Distinct signaling pathways activated by \u2018extracellular\u2019 and \u2018intracellular\u2019 serotonin in heart valve development and disease. Cell Biochem. Biophys. 67, 819\u2013828 (2013).","journal-title":"Cell Biochem. Biophys."},{"key":"608_CR38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/emm.2001.37","volume":"33","author":"BH Shah","year":"2001","unstructured":"Shah, B. H. et al. Molecular mechanisms involved in human platelet aggregation by synergistic interaction of platelet-activating factor and 5-hydroxytryptamine. Exp. Mol. Med. 33, 226\u2013233 (2001).","journal-title":"Exp. Mol. Med."},{"key":"608_CR39","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1021\/cr078224o","volume":"108","author":"DE Nichols","year":"2008","unstructured":"Nichols, D. E. & Nichols, C. D. Serotonin receptors. Chem. Rev. 108, 1614\u20131641 (2008).","journal-title":"Chem. Rev."},{"key":"608_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","volume":"71","author":"D Hoyer","year":"2002","unstructured":"Hoyer, D., Hannon, J. P. & Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71, 533\u2013554 (2002).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"608_CR41","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/0028-3908(84)90017-0","volume":"23","author":"PJ Conn","year":"1984","unstructured":"Conn, P. J. & Sanders-Bush, E. Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology 23, 993\u2013996 (1984).","journal-title":"Neuropharmacology"},{"key":"608_CR42","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1523\/JNEUROSCI.06-12-03669.1986","volume":"6","author":"PJ Conn","year":"1986","unstructured":"Conn, P. J. & Sanders-Bush, E. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J. Neurosci. 6, 3669\u20133675 (1986).","journal-title":"J. Neurosci."},{"key":"608_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1083\/jcb.200305129","volume":"163","author":"T Bisogno","year":"2003","unstructured":"Bisogno, T. et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463\u2013468 (2003).","journal-title":"J. Cell Biol."},{"key":"608_CR44","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1126\/science.1411571","volume":"258","author":"Y Nishizuka","year":"1992","unstructured":"Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607\u2013614 (1992).","journal-title":"Science"},{"key":"608_CR45","doi-asserted-by":"publisher","first-page":"16244","DOI":"10.1074\/jbc.M300544200","volume":"278","author":"M Trebak","year":"2003","unstructured":"Trebak, M., St. J. Bird, G., McKay, R. R., Birnbaumer, L. & Putney, J. W. Jr. Signaling mechanism for receptor-activated canonical transient receptor potential 3 (TRPC3) channels. J. Biol. Chem. 278, 16244\u201316252 (2003).","journal-title":"J. Biol. Chem."},{"key":"608_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/361315a0","volume":"361","author":"MJ Berridge","year":"1993","unstructured":"Berridge, M. J. Inositol trisphosphate and calcium signalling. Nature 361, 315\u2013325 (1993).","journal-title":"Nature"},{"key":"608_CR47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1146\/annurev.pharmtox.40.1.459","volume":"40","author":"VP Sah","year":"2000","unstructured":"Sah, V. P., Seasholtz, T. M., Sagi, S. A. & Brown, J. H. The role of Rho in G protein-coupled receptor signal transduction. Annu. Rev. Pharmacol. Toxicol. 40, 459\u2013489 (2000).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"608_CR48","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00702-009-0308-8","volume":"116","author":"NV Cozzi","year":"2009","unstructured":"Cozzi, N. V. et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J. Neural Transm. 116, 1591\u20131599 (2009).","journal-title":"J. Neural Transm."},{"key":"608_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/7854_2017_478","volume":"36","author":"JF L\u00f3pez-Gim\u00e9nez","year":"2018","unstructured":"L\u00f3pez-Gim\u00e9nez, J. F. & Gonz\u00e1lez-Maeso, J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr. Top. Behav. Neurosci. 36, 45\u201373 (2018).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"608_CR50","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman, R. B. et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836\u20132841 (2000).","journal-title":"Circulation"},{"key":"608_CR51","unstructured":"Nistala, P. 5-HT2B Receptor-Mediated Cardiac Valvulopathy. PhD thesis, Virginia Commonwealth Univ. (2018)."},{"key":"608_CR52","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1124\/jpet.106.117507","volume":"321","author":"PR Moya","year":"2007","unstructured":"Moya, P. R. et al. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J. Pharmacol. Exp. Ther. 321, 1054\u20131061 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"608_CR53","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1021\/jm060656o","volume":"49","author":"TH McLean","year":"2006","unstructured":"McLean, T. H. et al. 1-aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J. Med. Chem. 49, 5794\u20135803 (2006).","journal-title":"J. Med. Chem."},{"key":"608_CR54","doi-asserted-by":"crossref","unstructured":"Roth, B. L. The Serotonin Receptors: from Molecular Pharmacology to Human Therapeutics 1st edn (Humana Press, 2006).","DOI":"10.1007\/978-1-59745-080-5"},{"key":"608_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1568007043482598","volume":"3","author":"JE Leysen","year":"2004","unstructured":"Leysen, J. E. 5-HT2 receptors. Curr. Drug Targets CNS Neurol. Disord. 3, 11\u201326 (2004).","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"608_CR56","doi-asserted-by":"crossref","unstructured":"Vargas, M. V. et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379, 700\u2013706 (2023). A seminal preclinical study on the intracellular location of neural 5-HT2ARs.","DOI":"10.1126\/science.adf0435"},{"key":"608_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","volume":"49","author":"RJ Dinis-Oliveira","year":"2017","unstructured":"Dinis-Oliveira, R. J. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab. Rev. 49, 84\u201391 (2017).","journal-title":"Drug Metab. Rev."},{"key":"608_CR58","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/03602532.2019.1638931","volume":"51","author":"RF Lib\u00e2nio Os\u00f3rio Marta","year":"2019","unstructured":"Lib\u00e2nio Os\u00f3rio Marta, R. F. Metabolism of lysergic acid diethylamide (LSD): an update. Drug Metab. Rev. 51, 378\u2013387 (2019).","journal-title":"Drug Metab. Rev."},{"key":"608_CR59","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson, M., Richards, W. & Griffiths, R. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 22, 603\u2013620 (2008).","journal-title":"J. Psychopharmacol."},{"key":"608_CR60","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs, T. S. & Johansen, P. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J. Psychopharmacol. 26, 994\u20131002 (2012).","journal-title":"J. Psychopharmacol."},{"key":"608_CR61","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"30","author":"JJ Rucker","year":"2016","unstructured":"Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D. & Young, A. H. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J. Psychopharmacol. 30, 1220\u20131229 (2016).","journal-title":"J. Psychopharmacol."},{"key":"608_CR62","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/2045125316638008","volume":"6","author":"RG Dos Santos","year":"2016","unstructured":"Dos Santos, R. G. et al. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther. Adv. Psychopharmacol. 6, 193\u2013213 (2016).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"608_CR63","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","volume":"11","author":"RG Dos Santos","year":"2018","unstructured":"Dos Santos, R. G., Bouso, J. C., Alc\u00e1zar-C\u00f3rcoles, M. & Hallak, J. E. C. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev. Clin. Pharmacol. 11, 889\u2013902 (2018).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"608_CR64","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","volume":"48","author":"L Ley","year":"2023","unstructured":"Ley, L. et al. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology 48, 1659\u20131667 (2023).","journal-title":"Neuropsychopharmacology"},{"key":"608_CR65","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","volume":"239","author":"F Holze","year":"2022","unstructured":"Holze, F., Caluori, T. V., Vizeli, P. & Liechti, M. E. Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology 239, 1893\u20131905 (2022).","journal-title":"Psychopharmacology"},{"key":"608_CR66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler, F., Grimberg, U., Benz, M. A., Huber, T. & Vollenweider, F. X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose\u2013effect study. Psychopharmacology 172, 145\u2013156 (2004).","journal-title":"Psychopharmacology"},{"key":"608_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02477-4","volume":"13","author":"SB Vogt","year":"2023","unstructured":"Vogt, S. B. et al. Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl. Psychiatry 13, 172 (2023).","journal-title":"Transl. Psychiatry"},{"key":"608_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","volume":"143","author":"KAA Andersen","year":"2021","unstructured":"Andersen, K. A. A., Carhart-Harris, R., Nutt, D. J. & Erritzoe, D. Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr. Scand. 143, 101\u2013118 (2021).","journal-title":"Acta Psychiatr. Scand."},{"key":"608_CR69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yrtph.2013.03.007","volume":"66","author":"J van Amsterdam","year":"2013","unstructured":"van Amsterdam, J., Pennings, E., Brunt, T. & van den Brink, W. Physical harm due to chronic substance use. Regul. Toxicol. Pharmacol. 66, 83\u201387 (2013).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"608_CR70","doi-asserted-by":"crossref","unstructured":"van Amsterdam, J., Nutt, D., Phillips, L. & van den Brink, W. European rating of drug harms. J. Psychopharmacol. 29, 655\u2013660 (2015). A study describing and rating the harm potential of recreational drugs performed by EU drug experts.","DOI":"10.1177\/0269881115581980"},{"key":"608_CR71","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1360-0443.2004.00744.x","volume":"99","author":"RS Gable","year":"2004","unstructured":"Gable, R. S. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99, 686\u2013696 (2004).","journal-title":"Addiction"},{"key":"608_CR72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2004.03.003","volume":"102","author":"JH Halpern","year":"2004","unstructured":"Halpern, J. H. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol. Ther. 102, 131\u2013138 (2004).","journal-title":"Pharmacol. Ther."},{"key":"608_CR73","unstructured":"O\u2019Neil, M. J. The Merck Index: an Encyclopedia of Chemicals, Drugs, and Biologicals 13th edn (Merck, 2001)."},{"key":"608_CR74","unstructured":"US Drug Enforcement Administration, Diversion Control Division. Drug and Chemical Information (US Department of Justice, 2022)."},{"key":"608_CR75","unstructured":"US Drug Enforcement Administration, Diversion Control Division. Drug and Chemical Information (US Department of Justice, 2019)."},{"key":"608_CR76","unstructured":"Buckingham, J. Dictionary of Natural Products (CRC Press, 2004)."},{"key":"608_CR77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0278-6915(95)00093-3","volume":"34","author":"JJ Barone","year":"1996","unstructured":"Barone, J. J. & Roberts, H. R. Caffeine consumption. Food Chem. Toxicol. 34, 119\u2013129 (1996).","journal-title":"Food Chem. Toxicol."},{"key":"608_CR78","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1111\/j.1750-3841.2010.01561.x","volume":"75","author":"MA Heckman","year":"2010","unstructured":"Heckman, M. A., Weil, J. & Gonzalez de Mejia, E. Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. J. Food Sci. 75, R77\u2013R87 (2010).","journal-title":"J. Food Sci."},{"key":"608_CR79","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","volume":"59","author":"J van Amsterdam","year":"2011","unstructured":"van Amsterdam, J., Opperhuizen, A. & van den Brink, W. Harm potential of magic mushroom use: a review. Regul. Toxicol. Pharmacol. 59, 423\u2013429 (2011).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"608_CR80","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.lfs.2006.06.010","volume":"79","author":"J van Amsterdam","year":"2006","unstructured":"van Amsterdam, J., Talhout, R., Vleeming, W. & Opperhuizen, A. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. Life Sci. 79, 1969\u20131973 (2006).","journal-title":"Life Sci."},{"key":"608_CR81","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.ijcard.2007.12.064","volume":"134","author":"HM Nef","year":"2009","unstructured":"Nef, H. M. et al. Apical regional wall motion abnormalities reminiscent to Tako\u2013Tsubo cardiomyopathy following consumption of psychoactive fungi. Int. J. Cardiol. 134, e39\u2013e41 (2009).","journal-title":"Int. J. Cardiol."},{"key":"608_CR82","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.12998\/wjcc.v7.i16.2330","volume":"7","author":"S Li","year":"2019","unstructured":"Li, S. et al. Cardiac arrhythmias and cardiac arrest related to mushroom poisoning: a case report. World J. Clin. Cases 7, 2330\u20132335 (2019).","journal-title":"World J. Clin. Cases"},{"key":"608_CR83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/15563659809162584","volume":"36","author":"KS Borowiak","year":"1998","unstructured":"Borowiak, K. S., Ciechanowski, K. & Waloszczyk, P. Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. J. Toxicol. Clin. Toxicol. 36, 47\u201349 (1998).","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"608_CR84","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1161\/01.STR.5.2.213","volume":"5","author":"AN Lieberman","year":"1974","unstructured":"Lieberman, A. N., Bloom, W., Kishore, P. S. & Lin, J. P. Carotid artery occlusion following ingestion of LSD. Stroke 5, 213\u2013215 (1974).","journal-title":"Stroke"},{"key":"608_CR85","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jvir.2008.05.008","volume":"19","author":"MV Raval","year":"2008","unstructured":"Raval, M. V., Gaba, R. C., Brown, K., Sato, K. T. & Eskandari, M. K. Percutaneous transluminal angioplasty in the treatment of extensive LSD-induced lower extremity vasospasm refractory to pharmacologic therapy. J. Vasc. Interv. Radiol. 19, 1227\u20131230 (2008).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"608_CR86","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","volume":"26","author":"AM Becker","year":"2023","unstructured":"Becker, A. M. et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int. J. Neuropsychopharmacol. 26, 97\u2013106 (2023).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"608_CR87","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze, F. et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 46, 537\u2013544 (2021).","journal-title":"Neuropsychopharmacology"},{"key":"608_CR88","doi-asserted-by":"crossref","unstructured":"Gergs, U. et al. Lysergic acid diethylamide stimulates cardiac human H2 histamine and cardiac human 5-HT4-serotonin receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 97, 221\u2013236 (2023). Preclinical study on the chronotropic effects of LSD mediated through 5-HT4R and H2-R.","DOI":"10.1007\/s00210-023-02591-6"},{"key":"608_CR89","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman, R. J. & Qualls, C. R. Dose\u2013response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch. Gen. Psychiatry 51, 85\u201397 (1994).","journal-title":"Arch. Gen. Psychiatry"},{"key":"608_CR90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","volume":"58","author":"WS Redfern","year":"2003","unstructured":"Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32\u201345 (2003).","journal-title":"Cardiovasc. Res."},{"key":"608_CR91","doi-asserted-by":"crossref","unstructured":"Hackl, B., Todt, H., Kubista, H., Hilber, K. & Koenig, X. Psilocybin therapy of psychiatric disorders is not hampered by hERG potassium channel-mediated cardiotoxicity. Int. J. Neuropsychopharmacol. 25, 280\u2013282 (2021). Preclinical study on hERG channel inhibition by psilocybin.","DOI":"10.1093\/ijnp\/pyab085"},{"key":"608_CR92","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2021","unstructured":"Becker, A. M. et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin. Pharmacol. Ther. 111, 886\u2013895 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"608_CR93","doi-asserted-by":"crossref","unstructured":"Dahmane, E., Hutson, P. R. & Gobburu, J. V. S. Exposure\u2013response analysis to assess the concentration\u2013QTc relationship of psilocybin\/psilocin. Clin. Pharmacol. Drug Dev. 10, 78\u201385 (2021). Clinical study on the pharmacokinetics of psilocybin-induced QTc prolongation.","DOI":"10.1002\/cpdd.796"},{"key":"608_CR94","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","volume":"56","author":"RT Brown","year":"2017","unstructured":"Brown, R. T. et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin. Pharmacokinet. 56, 1543\u20131554 (2017).","journal-title":"Clin. Pharmacokinet."},{"key":"608_CR95","doi-asserted-by":"publisher","first-page":"122486","DOI":"10.1016\/j.jchromb.2020.122486","volume":"1164","author":"KE Kolaczynska","year":"2021","unstructured":"Kolaczynska, K. E., Liechti, M. E. & Duthaler, U. Development and validation of an LC\u2013MS\/MS method for the bioanalysis of psilocybin\u2019s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1164, 122486 (2021).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"608_CR96","unstructured":"Borowiak, K. Psilocin multiple intake resulted and in cardiotoxic effects. Acta Toxicol. 14, 23\u201330 (2006)."},{"key":"608_CR97","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: Revised Recommendations for Celexa (Citalopram Hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with High Doses (2012)."},{"key":"608_CR98","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1369-1600.2012.00447.x","volume":"19","author":"X Koenig","year":"2014","unstructured":"Koenig, X., Kovar, M., Boehm, S., Sandtner, W. & Hilber, K. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addict. Biol. 19, 237\u2013239 (2014).","journal-title":"Addict. Biol."},{"key":"608_CR99","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1749-6632.1998.tb08242.x","volume":"844","author":"DC Mash","year":"1998","unstructured":"Mash, D. C. et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann. N. Y. Acad. Sci. 844, 274\u2013292 (1998).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"608_CR100","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","volume":"914","author":"DC Mash","year":"2000","unstructured":"Mash, D. C. et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann. N. Y. Acad. Sci. 914, 394\u2013401 (2000).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"608_CR101","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.taap.2013.05.012","volume":"273","author":"X Koenig","year":"2013","unstructured":"Koenig, X. et al. Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug\u2019s cardiac ion channel profile. Toxicol. Appl. Pharmacol. 273, 259\u2013268 (2013).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"608_CR102","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12012-016-9366-y","volume":"17","author":"L Rubi","year":"2017","unstructured":"Rubi, L., Eckert, D., Boehm, S., Hilber, K. & Koenig, X. Anti-addiction drug ibogaine prolongs the action potential in human induced pluripotent stem cell-derived cardiomyocytes. Cardiovasc. Toxicol. 17, 215\u2013218 (2017).","journal-title":"Cardiovasc. Toxicol."},{"key":"608_CR103","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/cpdd.254","volume":"5","author":"P Glue","year":"2016","unstructured":"Glue, P. et al. Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clin. Pharmacol. Drug Dev. 5, 460\u2013468 (2016).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"608_CR104","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jcph.404","volume":"55","author":"P Glue","year":"2015","unstructured":"Glue, P. et al. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J. Clin. Pharmacol. 55, 189\u2013194 (2015).","journal-title":"J. Clin. Pharmacol."},{"key":"608_CR105","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1556-4029.2011.02008.x","volume":"57","author":"KR Alper","year":"2012","unstructured":"Alper, K. R., Staji\u0107, M. & Gill, J. R. Fatalities temporally associated with the ingestion of ibogaine. J. Forensic Sci. 57, 398\u2013412 (2012).","journal-title":"J. Forensic Sci."},{"key":"608_CR106","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/joa3.12061","volume":"34","author":"C Steinberg","year":"2018","unstructured":"Steinberg, C. & Deyell, M. W. Cardiac arrest after ibogaine intoxication. J. Arrhythm. 34, 455\u2013457 (2018).","journal-title":"J. Arrhythm."},{"key":"608_CR107","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12024-020-00342-0","volume":"17","author":"T A\u0107imovi\u0107","year":"2021","unstructured":"A\u0107imovi\u0107, T. et al. Death due to consumption of ibogaine: case report. Forensic Sci. Med. Pathol. 17, 126\u2013129 (2021).","journal-title":"Forensic Sci. Med. Pathol."},{"key":"608_CR108","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/bs.pbr.2018.08.005","volume":"242","author":"JM Corkery","year":"2018","unstructured":"Corkery, J. M. Ibogaine as a treatment for substance misuse: potential benefits and practical dangers. Prog. Brain Res. 242, 217\u2013257 (2018).","journal-title":"Prog. Brain Res."},{"key":"608_CR109","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.1166127","volume":"323","author":"D Fontanilla","year":"2009","unstructured":"Fontanilla, D. et al. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323, 934\u2013937 (2009).","journal-title":"Science"},{"key":"608_CR110","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","volume":"131","author":"T Hayashi","year":"2007","unstructured":"Hayashi, T. & Su, T. P. Sigma-1 receptor chaperones at the ER\u2013mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 131, 596\u2013610 (2007).","journal-title":"Cell"},{"key":"608_CR111","doi-asserted-by":"publisher","first-page":"C1049","DOI":"10.1152\/ajpcell.00431.2008","volume":"296","author":"M Johannessen","year":"2009","unstructured":"Johannessen, M. et al. Voltage-gated sodium channel modulation by sigma-receptors in cardiac myocytes and heterologous systems. Am. J. Physiol. Cell Physiol. 296, C1049\u2013C1057 (2009).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"608_CR112","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1124\/jpet.105.084152","volume":"313","author":"H Zhang","year":"2005","unstructured":"Zhang, H. & Cuevas, J. Sigma receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J. Pharmacol. Exp. Ther. 313, 1387\u20131396 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"608_CR113","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1152\/jn.2002.87.6.2867","volume":"87","author":"H Zhang","year":"2002","unstructured":"Zhang, H. & Cuevas, J. Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons. J. Neurophysiol. 87, 2867\u20132879 (2002).","journal-title":"J. Neurophysiol."},{"key":"608_CR114","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0022-3565(25)38880-4","volume":"269","author":"C Ela","year":"1994","unstructured":"Ela, C., Barg, J., Vogel, Z., Hasin, Y. & Eilam, Y. Sigma receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. J. Pharmacol. Exp. Ther. 269, 1300\u20131309 (1994).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"608_CR115","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0014-2999(95)00424-J","volume":"286","author":"M Novakova","year":"1995","unstructured":"Novakova, M. et al. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur. J. Pharmacol. 286, 19\u201330 (1995).","journal-title":"Eur. J. Pharmacol."},{"key":"608_CR116","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0014-2999(98)00398-7","volume":"353","author":"M Novakova","year":"1998","unstructured":"Novakova, M., Ela, C., Bowen, W. D., Hasin, Y. & Eilam, Y. Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Eur. J. Pharmacol. 353, 315\u2013327 (1998).","journal-title":"Eur. J. Pharmacol."},{"key":"608_CR117","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0014-2999(95)00750-4","volume":"295","author":"C Ela","year":"1996","unstructured":"Ela, C., Hasin, Y. & Eilam, Y. Apparent desensitization of a sigma receptor sub-population in neonatal rat cardiac myocytes by pre-treatment with sigma receptor ligands. Eur. J. Pharmacol. 295, 275\u2013280 (1996).","journal-title":"Eur. J. Pharmacol."},{"key":"608_CR118","doi-asserted-by":"publisher","first-page":"118047","DOI":"10.1016\/j.lfs.2020.118047","volume":"257","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Chronic stimulation of the sigma-1 receptor ameliorates ventricular ionic and structural remodeling in a rodent model of depression. Life Sci. 257, 118047 (2020).","journal-title":"Life Sci."},{"key":"608_CR119","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1620\/tjem.236.199","volume":"236","author":"T Stracina","year":"2015","unstructured":"Stracina, T. et al. Long-term haloperidol treatment prolongs QT interval and increases expression of sigma 1 and IP3 receptors in guinea pig hearts. Tohoku J. Exp. Med. 236, 199\u2013207 (2015).","journal-title":"Tohoku J. Exp. Med."},{"key":"608_CR120","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1476-5381.1989.tb12031.x","volume":"97","author":"N Ogata","year":"1989","unstructured":"Ogata, N. & Narahashi, T. Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. Br. J. Pharmacol. 97, 905\u2013913 (1989).","journal-title":"Br. J. Pharmacol."},{"key":"608_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-6-34","volume":"6","author":"CF Dahl","year":"2008","unstructured":"Dahl, C. F., Allen, M. R., Urie, P. M. & Hopkins, P. N. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med. 6, 34 (2008).","journal-title":"BMC Med."},{"key":"608_CR122","doi-asserted-by":"publisher","first-page":"50","DOI":"10.7326\/0003-4819-117-1-50","volume":"117","author":"MM Redfield","year":"1992","unstructured":"Redfield, M. M., Nicholson, W. J., Edwards, W. D. & Tajik, A. J. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann. Intern. Med. 117, 50\u201352 (1992).","journal-title":"Ann. Intern. Med."},{"key":"608_CR123","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. & Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356, 29\u201338 (2007).","journal-title":"N. Engl. J. Med."},{"key":"608_CR124","doi-asserted-by":"crossref","unstructured":"Droogmans, S. et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am. J. Cardiol. 100, 1442\u20131445 (2007). Clinical echocardiographic study on chronic MDMA use and VHD.","DOI":"10.1016\/j.amjcard.2007.06.045"},{"key":"608_CR125","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly, H. M. et al. Valvular heart disease associated with fenfluramine\u2013phentermine. N. Engl. J. Med. 337, 581\u2013588 (1997).","journal-title":"N. Engl. J. Med."},{"key":"608_CR126","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/hrt.70.6.537","volume":"70","author":"F Brenot","year":"1993","unstructured":"Brenot, F. et al. Primary pulmonary hypertension and fenfluramine use. Br. Heart J. 70, 537\u2013541 (1993).","journal-title":"Br. Heart J."},{"key":"608_CR127","doi-asserted-by":"publisher","first-page":"L471","DOI":"10.1152\/ajplung.00071.2008","volume":"295","author":"Y Liu","year":"2008","unstructured":"Liu, Y. & Fanburg, B. L. Phospholipase D signaling in serotonin-induced mitogenesis of pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L471\u2013L478 (2008).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"608_CR128","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.placenta.2004.08.003","volume":"26","author":"B Sonier","year":"2005","unstructured":"Sonier, B., Lavigne, C., Arseneault, M., Ouellette, R. & Vaillancourt, C. Expression of the 5-HT2A serotoninergic receptor in human placenta and choriocarcinoma cells: mitogenic implications of serotonin. Placenta 26, 484\u2013490 (2005).","journal-title":"Placenta"},{"key":"608_CR129","doi-asserted-by":"publisher","first-page":"21004","DOI":"10.1074\/jbc.M512096200","volume":"281","author":"M G\u00f6\u0151z","year":"2006","unstructured":"G\u00f6\u0151z, M., G\u00f6\u0151z, P., Luttrell, L. M. & Raymond, J. R. 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-\u03b1-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J. Biol. Chem. 281, 21004\u201321012 (2006).","journal-title":"J. Biol. Chem."},{"key":"608_CR130","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11010-014-2194-0","volume":"397","author":"C Chen","year":"2014","unstructured":"Chen, C. et al. Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-\u03b21\/Smad3-mediated fibrotic responses through 5-HT2A receptors. Mol. Cell. Biochem. 397, 267\u2013276 (2014).","journal-title":"Mol. Cell. Biochem."},{"key":"608_CR131","first-page":"827","volume":"10","author":"NM Rajamannan","year":"2001","unstructured":"Rajamannan, N. M. et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J. Heart Valve Dis. 10, 827\u2013831 (2001).","journal-title":"J. Heart Valve Dis."},{"key":"608_CR132","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","volume":"92","author":"PA Robiolio","year":"1995","unstructured":"Robiolio, P. A. et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92, 790\u2013795 (1995).","journal-title":"Circulation"},{"key":"608_CR133","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"BL Roth","year":"2007","unstructured":"Roth, B. L. Drugs and valvular heart disease. N. Engl. J. Med. 356, 6\u20139 (2007).","journal-title":"N. Engl. J. Med."},{"key":"608_CR134","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0192623310378027","volume":"38","author":"CS Elangbam","year":"2010","unstructured":"Elangbam, C. S. Drug-induced valvulopathy: an update. Toxicol. Pathol. 38, 837\u2013848 (2010).","journal-title":"Toxicol. Pathol."},{"key":"608_CR135","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s002130100749","volume":"156","author":"NE Rowland","year":"2001","unstructured":"Rowland, N. E., Robertson, K., Lo, J. & Rema, E. Cross tolerance between anorectic action and induction of Fos-ir with dexfenfluramine and 5HT1B\/2C agonists in rats. Psychopharmacology 156, 108\u2013114 (2001).","journal-title":"Psychopharmacology"},{"key":"608_CR136","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s002130050952","volume":"143","author":"SP Vickers","year":"1999","unstructured":"Vickers, S. P., Clifton, P. G., Dourish, C. T. & Tecott, L. H. Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 143, 309\u2013314 (1999).","journal-title":"Psychopharmacology"},{"key":"608_CR137","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0028-3908(01)00063-6","volume":"41","author":"SP Vickers","year":"2001","unstructured":"Vickers, S. P., Dourish, C. T. & Kennett, G. A. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41, 200\u2013209 (2001).","journal-title":"Neuropharmacology"},{"key":"608_CR138","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","volume":"57","author":"LW Fitzgerald","year":"2000","unstructured":"Fitzgerald, L. W. et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57, 75\u201381 (2000).","journal-title":"Mol. Pharmacol."},{"key":"608_CR139","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cob.12159","volume":"6","author":"FL Greenway","year":"2016","unstructured":"Greenway, F. L., Shanahan, W., Fain, R., Ma, T. & Rubino, D. Safety and tolerability review of lorcaserin in clinical trials. Clin. Obes. 6, 285\u2013295 (2016).","journal-title":"Clin. Obes."},{"key":"608_CR140","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","volume":"132","author":"JD Hutcheson","year":"2011","unstructured":"Hutcheson, J. D., Setola, V., Roth, B. L. & Merryman, W. D. Serotonin receptors and heart valve disease\u2014it was meant 2B. Pharmacol. Ther. 132, 146\u2013157 (2011).","journal-title":"Pharmacol. Ther."},{"key":"608_CR141","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","volume":"63","author":"V Setola","year":"2003","unstructured":"Setola, V. et al. 3,4-methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63, 1223\u20131229 (2003).","journal-title":"Mol. Pharmacol."},{"key":"608_CR142","doi-asserted-by":"crossref","unstructured":"Huang, X. P. et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. Mol. Pharmacol. 76, 710\u2013722 (2009). Preclinical study on the functional selectivity of different 5-HT2BR agonists.","DOI":"10.1124\/mol.109.058057"},{"key":"608_CR143","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1124\/jpet.110.173948","volume":"336","author":"T Kenakin","year":"2011","unstructured":"Kenakin, T. Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336, 296\u2013302 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"608_CR144","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1126\/science.1109237","volume":"308","author":"RJ Lefkowitz","year":"2005","unstructured":"Lefkowitz, R. J. & Shenoy, S. K. Transduction of receptor signals by \u03b2-arrestins. Science 308, 512\u2013517 (2005).","journal-title":"Science"},{"key":"608_CR145","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006810","volume":"7","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Inhibition of 5-hydroxytryptamine receptor 2B reduced vascular restenosis and mitigated the \u03b2-arrestin2\u2013mammalian target of rapamycin\/p70S6K pathway. J. Am. Heart Assoc. 7, e006810 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"608_CR146","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1126\/science.1232808","volume":"340","author":"D Wacker","year":"2013","unstructured":"Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615\u2013619 (2013).","journal-title":"Science"},{"key":"608_CR147","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02791072.2014.877321","volume":"46","author":"A Emerson","year":"2014","unstructured":"Emerson, A., Pont\u00e9, L., Jerome, L. & Doblin, R. History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). J. Psychoactive Drugs 46, 27\u201336 (2014).","journal-title":"J. Psychoactive Drugs"},{"key":"608_CR148","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025\u20131033 (2021).","journal-title":"Nat. Med."},{"key":"608_CR149","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","volume":"237","author":"L Jerome","year":"2020","unstructured":"Jerome, L. et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237, 2485\u20132497 (2020).","journal-title":"Psychopharmacology"},{"key":"608_CR150","unstructured":"US Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry docket no. FDA-2023-D-1987 (Department of Health and Human Services, 2023)."},{"key":"608_CR151","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0022-3565(25)13032-2","volume":"253","author":"N Toda","year":"1990","unstructured":"Toda, N. & Okamura, T. Comparison of the response to 5-carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries. J. Pharmacol. Exp. Ther. 253, 676\u2013682 (1990).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"608_CR152","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pharmthera.2004.08.005","volume":"104","author":"T Nagatomo","year":"2004","unstructured":"Nagatomo, T., Rashid, M., Abul Muntasir, H. & Komiyama, T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol. Ther. 104, 59\u201381 (2004).","journal-title":"Pharmacol. Ther."},{"key":"608_CR153","doi-asserted-by":"crossref","unstructured":"Altura, B. T. & Altura, B. M. Phencyclidine, lysergic acid diethylamide, and mescaline: cerebral artery spasms and hallucinogenic activity. Science 212, 1051\u20131052 (1981). Preclinical study on the vasoconstrictor effects of LSD and mescaline.","DOI":"10.1126\/science.7195070"},{"key":"608_CR154","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.1840180224","volume":"18","author":"M Fern\u00e1ndez","year":"1993","unstructured":"Fern\u00e1ndez, M. et al. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology 18, 389\u2013393 (1993).","journal-title":"Hepatology"},{"key":"608_CR155","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.brainres.2004.03.058","volume":"1014","author":"Y Ootsuka","year":"2004","unstructured":"Ootsuka, Y., Nalivaiko, E. & Blessing, W. W. Spinal 5-HT2A receptors regulate cutaneous sympathetic vasomotor outflow in rabbits and rats; relevance for cutaneous vasoconstriction elicited by MDMA (3,4-methylenedioxymethamphetamine, \u2018ecstasy\u2019) and its reversal by clozapine. Brain Res. 1014, 34\u201344 (2004).","journal-title":"Brain Res."},{"key":"608_CR156","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1476-5381.1978.tb17301.x","volume":"64","author":"L Edvinsson","year":"1978","unstructured":"Edvinsson, L. & Hardebo, J. E. Demonstration of 5-hydroxytryptamine receptors through inhibition by methergoline in cat pial arteries in vitro. Br. J. Pharmacol. 64, 281\u2013283 (1978).","journal-title":"Br. J. Pharmacol."},{"key":"608_CR157","first-page":"366","volume":"184","author":"DC Dyer","year":"1973","unstructured":"Dyer, D. C. & Gant, D. W. Vasoconstriction produced by hallucinogens on isolated human and sheep umbilical vasculature. J. Pharmacol. Exp. Ther. 184, 366\u2013375 (1973).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"608_CR158","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/01.CIR.90.3.1141","volume":"90","author":"AJ Kaumann","year":"1994","unstructured":"Kaumann, A. J., Frenken, M., Posival, H. & Brown, A. M. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D \u03b2 receptors. Circulation 90, 1141\u20131153 (1994).","journal-title":"Circulation"},{"key":"608_CR159","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1176\/ajp.114.4.309","volume":"114","author":"A Dimascio","year":"1957","unstructured":"Dimascio, A., Greenblatt, M. & Hyde, R. W. A study of the effects of L.S.D.: physiologic and psychological changes and their interrelations. Am. J. Psychiatry 114, 309\u2013317 (1957).","journal-title":"Am. J. Psychiatry"},{"key":"608_CR160","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1749-6632.1957.tb40742.x","volume":"66","author":"L Sokoloff","year":"1957","unstructured":"Sokoloff, L., Perlin, S., Kornetsky, C. & Kety, S. S. The effects of d-lysergic acid diethylamide on cerebral circulation and overall metabolism. Ann. N. Y. Acad. Sci. 66, 468\u2013477 (1957).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"608_CR161","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/archneurpsyc.1957.02330360115013","volume":"77","author":"C Kornetsky","year":"1957","unstructured":"Kornetsky, C. Relation of physiological and psychological effects of lysergic acid diethylamide. AMA Arch. Neurol. Psychiatry 77, 657\u2013658 (1957).","journal-title":"AMA Arch. Neurol. Psychiatry"},{"key":"608_CR162","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/10641969409078025","volume":"16","author":"K Chaouche-Teyara","year":"1994","unstructured":"Chaouche-Teyara, K., Fournier, B., Safar, M. & Dabir\u00e9, H. Systemic and regional haemodynamic effects of 1-(2,5-dimethoxy-4-iodo-phenyl)-2-aminopropane (DOI) and \u03b1-methyl-5-HT, in the anaesthetised rat. Clin. Exp. Hypertens. 16, 779\u2013798 (1994).","journal-title":"Clin. Exp. Hypertens."},{"key":"608_CR163","doi-asserted-by":"crossref","unstructured":"Pitol, D. L. et al. Ayahuasca alters structural parameters of the rat aorta. J. Cardiovasc. Pharmacol. 66, 58\u201362 (2015). Preclinical study linking chronic ayahuasca use to hypertensive structural changes in the rat aorta.","DOI":"10.1097\/FJC.0000000000000243"},{"key":"608_CR164","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll, C. U. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16, 163\u2013180 (2017).","journal-title":"World Psychiatry"},{"key":"608_CR165","doi-asserted-by":"crossref","unstructured":"Nkadimeng, S. M., Steinmann, C. M. L. & Eloff, J. N. Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes. Sci. Rep. 10, 22314 (2020). Preclinical study on the safety and potential therapeutic effects of psilocybin in an experimental model of cardiac hypertrophy.","DOI":"10.1038\/s41598-020-79328-5"},{"key":"608_CR166","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cellsig.2017.04.010","volume":"36","author":"CR Archer","year":"2017","unstructured":"Archer, C. R., Robinson, E. L., Drawnel, F. M. & Roderick, H. L. Endothelin-1 promotes hypertrophic remodelling of cardiac myocytes by activating sustained signalling and transcription downstream of endothelin type A receptors. Cell Signal. 36, 240\u2013254 (2017).","journal-title":"Cell Signal."},{"key":"608_CR167","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM199007263230405","volume":"323","author":"B Levine","year":"1990","unstructured":"Levine, B., Kalman, J., Mayer, L., Fillit, H. M. & Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236\u2013241 (1990).","journal-title":"N. Engl. J. Med."},{"key":"608_CR168","doi-asserted-by":"crossref","unstructured":"Flanagan, T. W. et al. Activation of 5-HT2 receptors reduces inflammation in vascular tissue and cholesterol levels in high-fat diet-fed apolipoprotein E knockout mice. Sci. Rep. 9, 13444 (2019). Preclinical study on the safety and potential therapeutic effects of DOI in a mouse model of atherosclerotic heart disease.","DOI":"10.1038\/s41598-019-49987-0"}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-025-00608-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-025-00608-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-025-00608-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T18:03:11Z","timestamp":1739469791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-025-00608-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":168,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1038\/s44161-025-00608-2","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.N. has no competing interests. L.M.P. consulted for Abbott, Anumana, Medtronic, Moderna and Voiant. He received a research grant from Anumana. He holds options for and sits on the advisory board of Anumana. JNR consulted for Advanced Medical Education, Foghorn Therapeutics, Jazz Pharma, Sanofi, Treeline Bio, Vertex and aMoon and sits on the scientific advisory board of Acesion Pharma, LuxMed and InCarda, the DSMB for the Baim Institute\u2013Lexeo and the scientific steering committee for the Janssen Heartline Study and holds options in Celero, Element Science, InfoBionic and NewPace. None of the interests for L.M.P. and J.N.R. are related to the subject matter of this Review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}